A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Brodalumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 21 Apr 2015 According to media release, status changed from recruiting to discontinued.
- 23 Nov 2014 Planned End Date changed from 1 Feb 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.